Mass General for Children has developed and evaluated modifications to existing U.S. clinical criteria that may help healthcare professionals more readily identify anaphylaxis in young children, particularly infants and then toddlers.
The modified criteria account for age-specific signs and symptoms that are often overlooked or under-recognized in the recognition of anaphylaxis in young children such as an inability to verbalize subjective symptoms, among other key age-related differences.
BOSTON – A Mass General team has developed modified criteria that may help healthcare professionals more accurately identify anaphylaxis, a potentially life-threatening allergic reaction, in infants and young children.
In a study published in the Journal of Allergy and Clinical Immunology: In Practice, researchers cited an urgent need for training clinicians to recognize and manage anaphylaxis in this young patient population that is often difficult to diagnose.
“Infants and toddlers under three can be a challenge to evaluate, in part because of their limited ability to communicate symptoms,” says senior author Michael Pistiner, MD, MMSc, Director of Food Allergy Advocacy, Education and Prevention at Mass General for Children. “We’re proposing modifications to current anaphylaxis criteria that consider age-specific symptoms and signs that are often overlooked or under-recognized. We believe our work will lead to more widespread recognition of a condition which is a true medical emergency.”
Anaphylaxis is a serious systemic allergic reaction with a rapid onset that can result in death if not quickly treated. Among its common triggers are bee stings, peanuts, shellfish, and some medications.
Over the last few decades, increasing rates of anaphylaxis have been reported worldwide, particularly in infants. In the U.S., hospitalizations among children from food-induced anaphylaxis have been on the rise.
In 2006, the National Institute of Allergy and Infectious Diseases and the Food Allergy and Anaphylaxis Network (NIAID-FAAN) proposed and adopted criteria designed to help clinicians identify patients likely to be experiencing anaphylaxis.
In 2020, the World Allergy Organization (WAO) proposed modifications, though neither organization’s criteria have been validated in infants and toddlers less than two years of age.
Mass General researchers set out to fill the gaps they perceived in those guidelines by identifying signs and symptoms that more precisely capture anaphylaxis in young children and incorporating them into a modified criteria.
In addition to commonly recognized symptoms like hives, swelling and vomiting their modifications include less recognized signs such as lethargy, inconsolability, coughing, diarrhea, cyanosis and rapid heart rate with no other explanation.
Based on a review of 337 cases of infants (less than 12 months), toddlers (12 to 36 months) and children (greater than 36 months) treated for suspected allergic or anaphylactic reactions in the pediatric emergency department of Mass General for Children, they evaluated their updated criteria against the current clinical standard.
They found that the NIAID/FAAN criteria identified 85 percent of all allergic/anaphylaxis encounters in the pediatric emergency department, while their expanded criteria captured 98 percent of such encounters.
Compared to existing standards, the modified criteria improved identification performance nearly 23 percent among infants, and more than 10 percent among toddlers.
“Some of our modifications are designed to accommodate the inability of infants to verbally express such symptoms as ‘my tummy hurts,’ ‘my tongue is itchy,’ or ‘I’m dizzy,’” explains Anna Handorf, MD, a pediatrics specialist at Mass General for Children and co-first author. “For these cases, we’ve added surrogate signs such as infants pulling their legs up to their chest, and crying as a proxy for abdominal pain.”
The team also emphasized the need for enhanced training nationally of healthcare professionals—particularly clinicians without extensive pediatric experience—to recognize the unique signs of anaphylaxis presentation in infants and toddlers.
“We believe our modified criteria can greatly decrease the number of infants and toddlers whose anaphylaxis goes unrecognized,” says Pistiner. “Future research will still be needed, including prospective, multicenter studies, to validate our findings.”
Pistiner is an assistant professor of Pediatrics at Harvard Medical School (HMS). Handorf is an instructor of Pediatrics at HMS. Co-first author Ian Roy, MPH, is a biostatistician at Mass General for Children. Other co-authors include Ari Cohen, MD, chief of Pediatric Emergency Medicine at Mass General for Children and assistant professor of Pediatrics at HMS; Carlos Camargo, Jr., MD, MPH, professor of Emergency Medicine at HMS; and Timothy Dribin, MD, associate professor at the University of Cincinnati College of Medicine.
